Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 13-valent pneumococcal conjugate vaccine versus 7-valent pneumococcal conjugate vaccine for nasopharyngeal colonization in healthy infants in Israel
2008-003708-77Phase 3
- Sponsor
- Pfizer
- Start
- Mar 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pneumococcal disease comparing 13-valent pneumococcal conjugate vaccine with 7-valent pneumococcal conjugate vaccine (2 arms). Primary endpoint: New acquisition of serotype 6A or 19A.
02
Drugs
pneumococcal 13-valent conjugate vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2008-003708-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003708-77.